Drugs / ChAdOx1.5T4
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02390063 | Jun 2015 → May 2018 | prostate cancer | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03815942 | Dec 2018 → Jun 2020 | castration-resistant prostate carcinoma | University of Oxford | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1.5T4 | “ChAdOx1.5T4 consists of a virus (ChAdOx1), which is a weakened version of a chimpanzee adenovirus that has been genetically altered so that it is impossible for it to grow in humans.” NCT03815942 ↗ |
| Action | Deplete | “This vaccine is intended to work by making the immune system kill cells that have a special protein (called 5T4) that is present on the surface of cancer cells.” NCT03815942 ↗ |
| Modality | Vaccine | “This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer.” NCT02390063 ↗ |
| Route | Intramuscular | “ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh)” NCT03815942 ↗ |